## a. Screening and Diagnosing Gestational Diabetes – Key Question 1

I. Coder Information					
RefID:	First Author:		Year:		
DE initials:	DV initials:		Other KQs: □2; □3; □4; □5		
II. Study Characterist	ics				
Country:	Publication type:	Publication type:		Study design:	
Centers:	Recruitment start date (	ment start date (e.g., Jan 1998):		Recruitment end date (e.g., Feb 2000):	
Funding: $\square$ Industry; $\square$ G	overnment;	e; □Foundat	tion;	$\square$ No funding; $\square$ Other; $\square$ ND	
If industry, specify firm*:	If "other," specify*:				
Blinding to test result:	Duration of followup:				
* Use "NR" if not reported  III. Selection Criteria a	nd Testing Conditions				
Inclusion criteria:	ind resting conditions	Exclusion of	crite	ria:	
	Exclude pre-pregnancy (type 1, 2)? Exclude overt diabetes diagnosed during pregnancy?				
Did patients routinely unde	rgo early testing for over	t diabetes dur	ing <sub>J</sub>	pregnancy?	
Patients Enrolled Consecut	Oone: y (all comparator tests performed in all patients)				

If so, specify:

Random (comparator tests done in different patients)

Non-Random (comparator tests in different patients, select gp)

Yes No No ND

Reference standard reported?

GCT/GST? **OGTT?** Other test 1? Other test 2? Specify: Specify: Index test?: Index test?: Index test?: Index test?: Pre-test protocol (fast/diet): Pre-test protocol (fast/diet): Pre-test protocol (fast/diet): Pre-test protocol (fast/diet): Test Intervals: Test Intervals: Test Intervals: Test Intervals:  $\square$ Fasting;  $\square$ 1 hr;  $\square$ 2 hr;  $\square$ 3  $\square$ Fasting;  $\square$ 1 hr;  $\square$ 2 hr;  $\square$ 3  $\square$ Fasting:  $\square$ 1 hr:  $\square$ 2 hr:  $\square$ 3  $\square$ Fasting;  $\square 1$  hr;  $\square 2$  hr;  $\square 3$ hr hr hr Glucose load: Glucose load: Glucose load: Glucose load: Time of test (wks): Time of test (wks): Time of test (wks): Time of test (wks): Criteria: Criteria: Criteria: Criteria: ☐ ADA, year: ADA, year: ☐ ADA, year: ☐ ADA, year: ☐ CC, year:  $\square$  CC, year:  $\square$  CC, year:  $\square$  CC, year: ☐ NDDG, year: □ NDDG, year: □ NDDG, year: □ NDDG, year:

☐ WHO, year:

Brand of beverage\*:

Amount of liquid\*:

, year:

, year:

Measurements performed by trained staff?

Other1:

Other2:

 $\square$  NR

☐ WHO, year:

Brand of beverage\*:

Amount of liquid\*:

, year:

, year:

Other1:

Other2:

 $\square$  NR

Plasma glucose estimation method:

, year:

☐ WHO, year:

Brand of beverage\*:

Amount of liquid\*:

, year:

, year:

Other1:

Other2:

 $\square$  NR

Notes:

IV. Screening and Diagnostic Tests

Manufacturing company:

Brand of Glucose meter:

Manufacturing company:

☐ WHO, year:

Other2:

Central lab?

 $\square$  NR

☐ Other1: , year:

Brand of beverage\*:

Amount of liquid\*:

\*If not reported, use NR

## V. Study Arms

	Group 1	Group 2	Group 3	Group 4	TOTAL
Group label					
GCT: Fasting	±	±	±	±	±
GCT: 1hr	±	±	±	±	±
GCT: 2hr	±	±	±	±	±
GCT:3hr	±	±	±	±	±
OGTT: Fasting	±	±	±	±	±
OGTT: 1hr	±	±	±	±	±
OGTT: 2hr	±	±	±	±	±
OGTT: 3hr	±	±	±	±	±
Treatment status					
Glucose levels reported in the following units: mg/dL;mmol/L			Glucose levels reported as: ☐mean ± SD; ☐median ± IQR		
Are groups mutually exclusive?					

## I. Baseline Characteristics

	Group 1	Group 2	Group 3	Group 4	TOTAL
Pts enrolled, n					
Pts analyzed, n					
Withdrawals, n					
Age (yr),	±	±	±	±	±
$\square$ mean $\pm$ SD					
$\square$ median ± IQR					
Prepregn. weight,	±	±	±	±	±
□lb; □kg					
mean ± SD					
$\Box \text{median} \pm \text{IQR}$					
BMI, □	±	±	±	±	±
mean±SD					
☐median ± IQR					
SBP (mmHg),	±	±	±	±	±
$\square \text{mean} \pm \text{SD}$					
☐median ± IQR	C 1	C 2		C 4	TOTAL
TT 71 1.	Group 1	Group 2	Group 3	Group 4	TOTAL
White, n					
Black, n					
Hispanic, n					
Asian, n					
Other, n					
Gestation at time	±	±	±	±	±
of test (wk)					
$\square$ mean $\pm$ SD					
$\square$ median $\pm$ IQR					
Smoking, n					
Alcohol use, n					
Family history of					
1 uning motory of					

diabetes, n					
History of GDM,					
n					
Parity, n	0	0	0	0	0
	1	1	1	1	1
	≥2	≥2	≥2	≥2	≥2
Parity	±	±	±	±	±
$\square$ mean $\pm$ SD					
$\square$ median $\pm$ IQR					
Comorbidities, n					
Comments					
II. Conclu	sions				
Briefly paraphr	ase the author	r conclusions:			
REFERENCE	S TO BE CH	IECKED:			
ASSOCIATEI	D PUBLICA'	FIONS (list all se	parated by semi-c	colons):	
TISS SCHITTE	J I CDEICH	i i o i i o i i o i i o i i o i i o i o	paracea by semi t		